Rocuronium Accord

What Is Rocuronium Accord and What Is It Used For?

Quick Answer: Rocuronium Accord is a prescription-only neuromuscular blocking agent containing rocuronium bromide. It is used during general anesthesia to relax skeletal muscles, allowing anesthesiologists to place a breathing tube (endotracheal intubation) and surgeons to operate with a still, relaxed surgical field.

Rocuronium Accord contains the active ingredient rocuronium bromide, a synthetic aminosteroid non-depolarizing neuromuscular blocking agent (NMBA). It belongs to the World Health Organization (WHO) anatomical therapeutic chemical (ATC) class M03AC09 – other quaternary ammonium-containing muscle relaxants. The medicine is supplied as a clear, colorless to slightly brownish solution in a ready-to-use prefilled syringe containing 10 mg of rocuronium bromide per milliliter.

Skeletal muscle contraction depends on signal transmission across the neuromuscular junction, where motor neurons meet muscle fibers. Under normal conditions, nerve impulses trigger the release of acetylcholine, which binds to nicotinic acetylcholine receptors on the muscle membrane and initiates a contraction. Rocuronium competes with acetylcholine for these receptors, occupying them without activating contraction. The result is reversible skeletal muscle paralysis that allows controlled airway management and optimal surgical access.

In modern anesthesia practice, rocuronium has become one of the most widely used neuromuscular blocking agents worldwide. It was first introduced in the mid-1990s and rapidly gained acceptance due to its favorable pharmacological profile. Unlike depolarizing agents such as succinylcholine, rocuronium does not produce fasciculations (involuntary muscle twitching) prior to paralysis and is not associated with malignant hyperthermia, hyperkalemia, or masseter muscle spasm. The availability of sugammadex, a selective reversal agent, has further increased rocuronium's popularity by enabling rapid and complete reversal of blockade, even from deep levels.

The primary clinical indications for Rocuronium Accord include:

• Facilitation of endotracheal intubation: During induction of general anesthesia in adults and children, rocuronium relaxes the jaw, pharynx, vocal cords, and upper airway musculature, allowing smooth placement of an endotracheal tube for mechanical ventilation.
• Skeletal muscle relaxation during surgery: Abdominal, thoracic, orthopedic, microsurgical, and robotic procedures often require a still and relaxed operative field; rocuronium provides controllable, intermediate-duration blockade for these procedures.
• Rapid sequence intubation (RSI): At higher doses (0.9–1.2 mg/kg), Rocuronium Accord produces adequate intubating conditions within 45–60 seconds, providing a non-depolarizing alternative to succinylcholine for emergency airway control in adults.
• Adjunct in the adult intensive care unit (ICU): In selected adult patients with severe respiratory failure or increased intracranial pressure, short-term neuromuscular blockade may facilitate mechanical ventilation; however, prolonged ICU use should be minimized because of the risk of critical illness myopathy.

The prefilled syringe presentation of Rocuronium Accord is particularly valuable in time-critical clinical environments. Traditional ampoule-based formulations require the drug to be drawn up, labeled, and verified before administration – steps that take precious seconds during airway emergencies. Prefilled syringes eliminate these preparation steps, reduce the risk of drug substitution errors, and provide a sealed system that maintains sterility until the moment of use. This presentation aligns with international patient safety recommendations from the Association of Anaesthetists, the American Society of Anesthesiologists (ASA), and the Institute for Safe Medication Practices (ISMP) to use ready-to-administer injectables whenever feasible in high-acuity settings.

What Should You Know Before Receiving Rocuronium Accord?

Quick Answer: Rocuronium Accord must not be used in patients with known hypersensitivity to rocuronium bromide, the bromide ion, or any excipient. Particular caution is required in patients with neuromuscular disorders, hepatic or biliary disease, electrolyte imbalances, burns, obesity, or prior allergic reactions to any neuromuscular blocking agent.

Before administering Rocuronium Accord, the anesthesiology team will perform a thorough preoperative assessment, including a review of medical history, medication history, allergies, prior anesthetic experiences, and relevant laboratory values. Because the drug is administered almost exclusively in hospital settings by trained specialists, most of these precautions are managed by the clinician; however, patients and caregivers should be aware of the factors that influence safety.

Contraindications

Rocuronium Accord is absolutely contraindicated in the following situations:

• Known hypersensitivity to rocuronium bromide, the bromide ion, or any of the excipients listed in the product composition.
• Documented history of anaphylaxis to rocuronium specifically. Patients with prior severe reactions to other aminosteroid neuromuscular blocking agents (vecuronium, pancuronium) should be evaluated carefully, because cross-sensitivity is possible.

Cross-reactivity between neuromuscular blocking agents is well documented: the quaternary ammonium group common to all NMBAs is a frequent allergenic epitope. Patients with a history of intraoperative anaphylaxis should undergo allergological evaluation (skin prick testing, intradermal testing, and specific IgE assays where available) before receiving any NMBA, including rocuronium.

Warnings and Precautions

The anesthesiologist should be informed of all conditions and medications before rocuronium is administered, because several factors can significantly alter the drug's pharmacokinetics, pharmacodynamics, or safety profile:

• Previous allergic reactions to NMBAs: Any prior anaphylactic or anaphylactoid reaction to a neuromuscular blocking agent increases the risk of cross-reactivity with rocuronium. Full resuscitation readiness and careful titration are essential.
• Hepatic, biliary, or gallbladder disease: Rocuronium is primarily eliminated via hepatic uptake (approximately 70%) and biliary excretion. Liver cirrhosis, cholestasis, or biliary obstruction can significantly prolong the duration of action, sometimes up to two to three times the normal duration. Dose reductions of 25–50% and neuromuscular monitoring are strongly recommended.
• Renal impairment: Although renal elimination plays a smaller role (approximately 10–25%), severe renal failure can prolong the effects of rocuronium, particularly after repeated doses or continuous infusion.
• Cardiovascular disease: Rocuronium has minimal cardiovascular effects at standard doses, but altered circulation (heart failure, low cardiac output) can delay onset time because the drug reaches the neuromuscular junction more slowly.
• Edema and fluid overload: An increased volume of distribution can reduce peak plasma concentrations and delay onset.
• Neuromuscular disorders: Myasthenia gravis, Lambert-Eaton myasthenic syndrome, poliomyelitis sequelae, amyotrophic lateral sclerosis (ALS), and muscular dystrophies dramatically increase sensitivity to non-depolarizing NMBAs. Significantly reduced doses (often 10–20% of normal) and extensive neuromuscular monitoring are required.
• Hypothermia: Temperatures below 35°C slow the metabolism and clearance of rocuronium, prolonging its effects proportionally.
• Electrolyte imbalances: Hypocalcemia, hypokalemia, hypermagnesemia, and metabolic acidosis potentiate neuromuscular blockade. Correction of these disturbances should be considered where clinically feasible before surgery.
• Burns patients: Patients with major burns often develop resistance to non-depolarizing NMBAs due to up-regulation of acetylcholine receptors; higher doses may be required to achieve adequate blockade.
• Obesity: In patients with a body mass index above 30 kg/m², dosing should be based on ideal or lean body weight rather than actual body weight to avoid prolonged blockade and overdose.
• Elderly patients: Age-related declines in hepatic blood flow and renal function can prolong the duration of action; neuromuscular monitoring is particularly important in this population.
• Long QT syndrome and cardiac conduction disorders: While rocuronium itself does not prolong the QT interval, caution is advised when combined with other QT-prolonging anesthetic agents.

Pregnancy and Breastfeeding

Clinical data on the use of rocuronium during pregnancy remain limited. Animal reproduction studies have not revealed evidence of teratogenicity, embryotoxicity, or fetotoxicity at clinically relevant doses. However, controlled studies in pregnant women are lacking. Rocuronium should therefore be used during pregnancy only when the anticipated clinical benefit outweighs the potential risk to the fetus, and after discussion with an obstetric anesthesiologist where possible.

Rocuronium is approved and routinely used for induction of general anesthesia during cesarean section delivery, including rapid sequence intubation in obstetric emergencies. At typical doses (0.6–1.0 mg/kg) administered shortly before delivery, placental transfer is minimal, and neonatal muscle tone is generally preserved; however, neonatal monitoring is mandatory when the drug is used in the peripartum period.

There are no data regarding the excretion of rocuronium in human breast milk. Because the drug is administered in hospital settings for short-duration procedures and has a relatively short elimination half-life (1–2 hours in healthy adults), clinically significant exposure to a nursing infant is unlikely. Breastfeeding can generally be resumed once the mother has fully recovered from anesthesia. There are no available data regarding the effects of rocuronium on human fertility.

Driving and Operating Machinery

Rocuronium Accord has a significant effect on the ability to drive and use machinery, because it is administered as part of general anesthesia. Patients should not drive, ride a bicycle, use power tools, sign legal documents, or make important decisions for at least 24 hours after full recovery from anesthesia. Residual effects of concomitant anesthetic and analgesic medications may impair cognition and reaction time for longer. Patients should be accompanied home by a responsible adult after any outpatient procedure and should follow the specific postoperative instructions provided by the anesthesiology team.

How Does Rocuronium Accord Interact with Other Drugs?

Quick Answer: Many medications can enhance or reduce the effects of rocuronium, including volatile anesthetics, aminoglycoside antibiotics, magnesium salts, calcium channel blockers, lithium, corticosteroids, and anticonvulsants. The anesthesiologist will review all current medications before administering rocuronium and adjust doses accordingly.

Drug interactions with rocuronium are clinically significant because they can potentiate (increase) or antagonize (reduce) the degree and duration of neuromuscular blockade. These interactions may result in inadequate blockade, prolonged paralysis, recurarization after apparent recovery, or unexpected resistance to reversal agents. The anesthesiology team will consider all concurrent medications when calculating the appropriate dose and selecting a reversal strategy.

Drugs That Enhance Neuromuscular Blockade

The following medications may increase the intensity or prolong the duration of rocuronium's effects, potentially requiring dose reductions and extended monitoring:

Drugs That Reduce Neuromuscular Blockade

The following medications may reduce the efficacy of rocuronium, sometimes requiring substantially higher doses to achieve adequate blockade:

• Phenytoin and carbamazepine (chronic use): Long-term use of these anticonvulsants induces hepatic enzymes and increases rocuronium clearance, which can produce resistance and require dose increases of 50–80%. Acute single-dose administration may instead potentiate blockade.
• Theophylline and aminophylline: Through phosphodiesterase inhibition and increased intracellular calcium, these agents can antagonize neuromuscular blockade.
• Protease inhibitors and ritonavir-boosted regimens: May affect rocuronium metabolism through altered hepatic transport.
• Calcium salts (acute administration): May transiently antagonize blockade in the setting of hypocalcemia.
• Noradrenaline and azathioprine: Have been reported to reduce the intensity of blockade.
• Cholinesterase inhibitors (neostigmine, pyridostigmine, edrophonium): Increase acetylcholine availability and antagonize blockade; used therapeutically for reversal at the end of surgery.

Combination with Other Neuromuscular Blocking Agents

The combination of rocuronium with succinylcholine (a depolarizing agent) administered immediately afterwards can produce a complex, mixed block with unpredictable characteristics. Succinylcholine administered prior to rocuronium may produce either potentiation or antagonism depending on timing. Combining rocuronium with other non-depolarizing NMBAs such as vecuronium, pancuronium, or cis-atracurium is occasionally used to adjust blockade profiles but requires careful neuromuscular monitoring.

What Is the Correct Dosage of Rocuronium Accord?

Quick Answer: The standard adult intubating dose is 0.6 mg/kg body weight, producing adequate intubating conditions within 60–90 seconds and a duration of 30–40 minutes. For rapid sequence intubation, 0.9–1.2 mg/kg is used. Dose adjustments are required based on age, hepatic function, concurrent medications, and individual response, with neuromuscular monitoring strongly recommended.

Rocuronium Accord is administered intravenously as a single bolus injection, repeated boluses, or continuous infusion. The dose is individualized based on the patient's body weight, age, clinical status, concurrent medications, type of anesthesia, and surgical requirements. Objective neuromuscular monitoring (e.g., train-of-four acceleromyography at the adductor pollicis muscle) is recommended to guide dosing, optimize the timing of reversal, and confirm adequate recovery before extubation.

The prefilled syringe presentation of Rocuronium Accord allows rapid, accurate delivery at the point of care without the need for drawing up from an ampoule, making it particularly suitable for rapid sequence intubation and emergency airway management.

Adults

Children and Adolescents

Rocuronium Accord can be administered to neonates (0–27 days), infants (28 days to 23 months), children (2–11 years), and adolescents (12–17 years). The standard intubating dose is the same as for adults (0.6 mg/kg), but the pharmacokinetics and pharmacodynamics vary significantly across pediatric age groups. Experience with rocuronium for rapid sequence intubation in children and adolescents is limited and is generally not routinely recommended for this indication.

Higher bolus doses (1.0 mg/kg) for intubation have been used in pediatric cardiac surgery and selected emergency scenarios, but data are limited. Sugammadex reversal dosing in children follows adult weight-based recommendations for moderate (2 mg/kg) and deep (4 mg/kg) blockade; it is not routinely recommended for immediate reversal of a 1.2 mg/kg dose in pediatric patients due to limited clinical data.

Elderly Patients

Elderly patients (over 65 years of age) may experience a prolonged duration of action because of age-related reductions in hepatic blood flow, hepatic enzyme function, and lean body mass. Onset time is generally comparable to younger adults, but recovery from neuromuscular blockade may be significantly delayed and more variable. The anesthesiologist will typically use standard intubating doses (0.6 mg/kg) but will monitor more closely, extend the interval between maintenance doses, and reduce infusion rates. Careful quantitative neuromuscular monitoring is particularly important in this population to avoid residual blockade, which is associated with increased postoperative pulmonary complications and prolonged hospital stays.

Hepatic and Renal Impairment

Patients with hepatic or biliary disease may show a modestly delayed onset and, more notably, a significantly prolonged duration of action, because rocuronium is primarily eliminated through hepatic uptake and biliary excretion. In moderate to severe hepatic impairment, dose reductions of 25–50% and extended monitoring are recommended. Repeated doses and continuous infusions should be used with particular caution because accumulation is more likely.

In renal impairment, standard single doses produce similar clinical effects to those seen in healthy patients, but repeated doses or continuous infusion may result in some accumulation and prolonged recovery, particularly in severe renal failure. Sugammadex–rocuronium complexes are eliminated renally, so sugammadex use in patients with severe renal failure (creatinine clearance below 30 ml/min) requires careful consideration.

Missed or Forgotten Dose

Because Rocuronium Accord is administered only in a supervised clinical setting as part of general anesthesia or intensive care, patients do not self-administer or schedule doses independently. There is no concept of a "missed dose" in the patient-administered sense. Maintenance dosing during surgery or ICU is adjusted continuously by the anesthesiology or critical care team based on clinical needs and neuromuscular monitoring.

Overdose and Management

Accidental overdose of rocuronium produces prolonged and profound neuromuscular blockade. Management focuses on maintaining adequate ventilation, oxygenation, and cardiovascular stability until neuromuscular function recovers. The key steps in overdose management are:

• Continued mechanical ventilation and sedation until the patient can breathe adequately and demonstrates full return of muscle strength.
• Sugammadex administration: Sugammadex is the preferred reversal agent and can rapidly reverse even deep and profound blockade at higher doses (up to 16 mg/kg for immediate reversal). This makes rocuronium overdose particularly manageable in settings where sugammadex is available.
• Alternative reversal: Neostigmine (0.04–0.07 mg/kg) combined with an anticholinergic agent (atropine or glycopyrrolate) may be used for moderate residual blockade but is ineffective for deep blockade.
• Objective monitoring: Quantitative neuromuscular monitoring is essential to confirm complete recovery (train-of-four ratio ≥ 0.9) before discontinuing ventilatory support and extubating the patient.
• Supportive care: Hemodynamic support, temperature management, and correction of electrolyte imbalances should be undertaken as clinically indicated.

What Are the Side Effects of Rocuronium Accord?

Quick Answer: The most commonly reported side effects of Rocuronium Accord are injection site pain, tachycardia (particularly in children), and transient changes in blood pressure. Serious but rare side effects include anaphylactic reactions, bronchospasm, prolonged neuromuscular blockade, and critical illness myopathy after prolonged ICU use.

Like all medicines, rocuronium can cause side effects, although not everyone experiences them. Most adverse reactions occur during or shortly after administration and are managed in real time by the anesthesiology team. The following adverse events have been reported in clinical trials and post-marketing surveillance, categorized by frequency according to the Medical Dictionary for Regulatory Activities (MedDRA) convention.

Anaphylaxis to Neuromuscular Blocking Agents

Although very rare, anaphylactic reactions to neuromuscular blocking agents represent one of the most common causes of perioperative anaphylaxis, with an incidence estimated at 1 in 10,000 to 1 in 20,000 anesthetics. Rocuronium has been identified in several national surveillance studies as one of the more frequently implicated agents, although absolute risk remains low. The risk appears higher in patients with previous exposure to NMBAs or to quaternary ammonium compounds, which are found in many cosmetics, detergents, and cough medicines (leading to potential sensitization before first medical exposure).

Patients with a history of severe allergic or anaphylactic reactions during anesthesia should be evaluated by an allergist before elective procedures. Skin prick testing, intradermal testing, and specific IgE assays can help identify patients at risk. In the event of suspected anaphylaxis during anesthesia, immediate treatment with intramuscular or intravenous epinephrine, aggressive fluid resuscitation, airway management, and supportive care should be provided, following established resuscitation protocols (e.g., Resuscitation Council UK, European Resuscitation Council, or American Heart Association guidelines).

Critical Illness Myopathy and Polyneuropathy

Prolonged administration of neuromuscular blocking agents in the ICU, particularly in combination with corticosteroids, is associated with the development of critical illness myopathy – a condition characterized by diffuse muscle weakness, difficulty weaning from mechanical ventilation, and prolonged recovery that can extend for weeks to months. The mechanism involves myofiber atrophy, thick-filament myosin loss, and functional denervation at the neuromuscular junction. To minimize risk, the duration of neuromuscular blockade in the ICU should be kept to the minimum necessary, daily drug holidays should be considered, and objective neuromuscular monitoring should be used.

Residual Neuromuscular Blockade

Incomplete recovery from neuromuscular blockade at the end of surgery (train-of-four ratio < 0.9 at extubation) is a common but underrecognized complication that increases the risk of postoperative pulmonary complications, including hypoxemia, aspiration, and reintubation. The routine use of quantitative neuromuscular monitoring and appropriate reversal with sugammadex (preferred) or neostigmine substantially reduces this risk.

Reporting Side Effects

If you experience any side effects after receiving Rocuronium Accord, speak to your anesthesiologist, surgeon, or another healthcare professional. You can also report side effects directly to national regulatory authorities such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA) MedWatch program, or the UK Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme. Reporting helps generate information about the safety of this medicine.

How Should You Store Rocuronium Accord?

Quick Answer: Store Rocuronium Accord prefilled syringes in a refrigerator at 2–8°C (36–46°F). The product may be stored outside the refrigerator at temperatures up to 25°C for a limited period as specified in the product information. Do not freeze. Use immediately after opening. Keep out of the reach and sight of children.

Proper storage of Rocuronium Accord is essential to maintain the potency, sterility, and safety of the medicine. Because it is used almost exclusively in hospital pharmacy and operating room settings, storage responsibilities typically rest with the institution; however, the following guidelines apply and should be observed whenever the product is handled.

• Temperature: Store in a refrigerator at 2–8°C (36–46°F). The prefilled syringes may be stored at room temperature (up to 25°C / 77°F) for a limited period as indicated in the product labelling. Do not freeze.
• Light protection: Store in the original carton to protect from light.
• Single use only: The prefilled syringe is intended for single use. Discard any unused solution after administration; do not save partially used syringes for later use.
• Dilution: When dilution is required for infusion, Rocuronium Accord is compatible with 0.9% sodium chloride solution and 5% glucose solution. Diluted solutions to 0.5 mg/ml or 0.1 mg/ml are chemically and physically stable for up to 24 hours at room temperature when exposed to ambient daylight in both glass and plastic containers. From a microbiological perspective, use immediately unless dilution is performed under validated aseptic conditions.
• Visual inspection: Before administration, inspect the solution visually. Do not use if the solution is not clear, if particles are visible, or if the syringe is damaged.
• Expiration date: Do not use Rocuronium Accord after the expiration date (EXP) printed on the syringe label and carton. The expiration date refers to the last day of the month indicated.
• Disposal: Medicines should not be disposed of via wastewater or household waste. Return unused or expired syringes to the pharmacy for environmentally appropriate disposal. These measures help protect the environment.
• Keep out of reach of children: Always store in a secure, locked location in healthcare facilities, inaccessible to children and unauthorized personnel.

What Does Rocuronium Accord Contain?

Quick Answer: Each milliliter of Rocuronium Accord contains 10 mg of rocuronium bromide as the active ingredient. Excipients typically include sodium acetate, sodium chloride, hydrochloric acid, sodium hydroxide (for pH adjustment), and water for injections.

Rocuronium Accord is a clear, colorless to slightly brownish-yellow, sterile solution for injection supplied in a ready-to-use prefilled syringe. The complete qualitative and quantitative composition is as follows:

Active Substance

• Rocuronium bromide: 10 mg per milliliter of solution.

Excipients (Inactive Ingredients)

The typical excipients for rocuronium bromide 10 mg/ml solution for injection include:

• Sodium acetate (as a buffer)
• Sodium chloride (for tonicity adjustment)
• Hydrochloric acid (for pH adjustment to approximately 4)
• Sodium hydroxide (for pH adjustment)
• Water for injections

The pH of the solution is approximately 4.0 (range 3.8–4.2), which contributes to the stability of the active ingredient. The exact composition may vary slightly between manufacturing batches and presentations; always refer to the current product information leaflet supplied with the package.

Sodium Content

Rocuronium Accord contains less than 1 mmol (23 mg) of sodium per dose, which means it is considered "essentially sodium-free". This is relevant for patients on strict sodium-restricted diets, those with severe congestive heart failure, or those receiving multiple intravenous medications where cumulative sodium load must be managed.

Packaging

Rocuronium Accord is available as prefilled syringes containing rocuronium bromide 10 mg/ml. Common pack sizes include 5 ml and 10 ml syringes, supplied in cartons appropriate for hospital pharmacy stock. Each syringe is individually packaged to maintain sterility until the moment of use.

Marketing Authorisation Holder and Manufacturer

Rocuronium Accord is marketed by Accord Healthcare, a global pharmaceutical company specializing in generic and specialty medicines. For full and current product information, refer to the Summary of Product Characteristics (SmPC) approved by the European Medicines Agency (EMA) or the relevant national regulatory authority in your jurisdiction.